Molecular Characterization of Polyomavirus-Positive and Negative Merkel Cell Carcinoma
Cancers · 31.10.2025 · 17 (21) · 3508
DOI: 10.3390/cancers17213508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 31.10.2025. Verfasst von Poorva Vaidya und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, UC Irvine School of Medicine, Orange, CA 92868, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background/Objectives: Immune checkpoint inhibitors (ICIs) are frontline treatment for advanced Merkel Cell Carcinoma (MCC), regardless of viral status. Frontline ICIs provide durable benefit to only half of patients, highlighting a need for alternative therapies. In this study, the objective is to leverage whole exome sequencing (WES) and transcriptome sequencing (WTS) to distinguish genomic alterations associated with ICI response. Investigate differential genomic alterations between virus-positive (VP) and virus-negative (VN)-MCC to identify novel therapeutic targets.
Methods
A total of 95 MCC cases underwent WES and WTS. Utilizing computational pipelines applied to WES, we identified viral status and tumor mutational burden (TMB). RNA-seq data was used to characterize the immune microenvironment.
Results
Of 95 MCC cases, 57 (60%) were VP-MCC and 38 (40%) were VN-MCC. Median TMB was higher in VN-MCC (27.5 vs. 1 Muts/Mb). Mutations in TP53, RB1, NOTCH1, KMTD2, KMT2C, and PIK3CA were primarily found in VN-MCC. MAPK Pathway Activity Score, NK cell infiltration, and the immune checkpoint gene CD276 in VN-MCC tumors were upregulated. No overall survival (OS) difference was identified between VP and VN-MCC, even after ICIs.
Conclusions
MCC oncogenesis and treatment response transcend viral status. While mutational analysis confirms previous findings, assessment of the transcriptome and tumor microenvironment suggests alternate therapeutic targets.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology/Oncology, UC Irvine School of Medicine, Orange, CA 92868, USA.
- Caris Life Sciences, Phoenix, AZ 85001, USA.
- Division of Medical Oncology and Hematology, Yale School of Medicine, New Haven, CT 06520, USA.
- Oregon Health & Science University, Portland, OR 97239, USA.
- Division of Hematology/Oncology and Transplantation, Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN 55455, USA.
- Department of Otolaryngology-Head & Neck Surgery, University of California, San Diego, CA 92093, USA.
ORCID-Profile: Poorva Vaidya, Dave Bryant, Curtis J Perry, Emil Lou, Theresa Guo, Isaac Brownell, Sourat Darabi
Förderung
- NCI NIH HHS
Zitieren
APA
Vaidya, P., Wu, S., Bryant, D., Perry, C. J., Prakash, V., Lou, E., Guo, T., Brownell, I., Darabi, S., Gao, L., Abdulla, F., & Park, S. J. (2025). Molecular Characterization of Polyomavirus-Positive and Negative Merkel Cell Carcinoma. Cancers, 17(21), 3508. https://doi.org/10.3390/cancers17213508
Vancouver
Vaidya P, Wu S, Bryant D, Perry CJ, Prakash V, Lou E, et al. Molecular Characterization of Polyomavirus-Positive and Negative Merkel Cell Carcinoma. Cancers. 2025;17(21):3508. doi:10.3390/cancers17213508
BibTeX
@article{Vaidya2025,
author = {Vaidya, Poorva and Wu, Sharon and Bryant, Dave and Perry, Curtis J and Prakash, Varsha and Lou, Emil and Guo, Theresa and Brownell, Isaac and Darabi, Sourat and Gao, Ling and Abdulla, Farah and Park, Soo J},
title = {Molecular Characterization of Polyomavirus-Positive and Negative Merkel Cell Carcinoma},
journal = {Cancers},
year = {2025},
volume = {17},
number = {21},
pages = {3508},
doi = {10.3390/cancers17213508}
}
EUVIMED